Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
1. The effect of ketanserin on digital blood flow and 5-hydroxytryptamine (5-HT)-induced platelet aggregation was studied in 18 patients with Raynaud's phenomenon. 2. Measurements were made before and after a single dose of 20 mg ketanserin and again after 1 month of continuous treatment with 20 mg ketanserin three times a day. 3. Digital blood flow was assessed by changes in digital pulse volume; platelet aggregation by changes in light transmission after challenge with 10(-5) M 5-HT. 4. Ketanserin induced a rise in digital blood flow and blocked the platelet response to 5-HT; the two events were not correlated and were independent of subjective improvement. 5. These data do not support the suggestion that 5-HT2-receptor blockade is of major importance in the dilatory effect of ketanserin in Raynaud's phenomenon.
Marasini
B
B
Clinica Medica, Ospedale S. Paolo, Università degli Studi di Milano, Italy.
Bassani
C
C
D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D005260:Female; D005385:Fingers / Q000098:blood supply; D006801:Humans; D007650:Ketanserin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011928:Raynaud Disease / Q000503:physiopathology*; D012595:Scleroderma, Systemic / Q000150:complications; D012701:Serotonin / Q000494:pharmacology*; D012702:Serotonin Antagonists; D014664:Vasodilation / Q000187:drug effects
D012702:Serotonin Antagonists; D012701:Serotonin; D007650:Ketanserin